Labcorp Stock - Baird nudges price target higher while consensus stays constructive
17.06.2026 - 16:39:02 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 16:35 CET. Details in the imprint.
Labcorp (US50540R4092) sits in the analyst spotlight this week as Wall Street fine-tunes its view on the diagnostics and laboratory services group. One notable move comes from Baird, which has in recent weeks inched its price target slightly higher while keeping an Outperform stance, according to broker research summaries.
All news and analysis on Labcorp stock
Stay on top of Labcorp developments, from earnings and guidance to analyst updates and regulatory filings, with the latest coverage and data highlights around the stock.
What recent analyst moves show
Broker compilation pages indicate that Baird has recently adjusted its price target on Labcorp shares, nudging it up by about $1 while reiterating an Outperform rating. The move underscores a broadly constructive stance on the stock within the healthcare providers and services space.
Other houses also keep positive or neutral views, leaving the overall recommendation skewed toward Buy-equivalent ratings. Against that backdrop, the modest target move from Baird is incremental rather than transformative, but it confirms sustained analyst confidence in Labcorp's fundamentals.
Consensus and valuation snapshot
Valuation data collated by TradingKey show Labcorp trading on a price-to-earnings ratio of around 23, placing it near the upper third of its historical range. The same source assigns the stock a valuation score above 9 on a 10-point scale within its industry peer set.
On the financial side, Labcorp generated roughly $3.54 billion in its latest reported quarter, a year-over-year increase of about 5.8%, according to TradingKey's financial health overview. That growth, paired with an operating efficiency described as high, helps explain why consensus remains relatively supportive despite a mature US diagnostics market.
How the company makes money
Labcorp earns most of its revenue from diagnostic laboratory testing and related services for physicians, hospitals, and drug developers. The group runs large networks of patient service centers and central laboratories, and it also provides central lab support for clinical trials and drug development projects for the biopharma industry.
Where the stock trades today
Labcorp shares (US50540R4092) most recently changed hands on the New York Stock Exchange at about $264.60 on 06/17/2026, 16:35 CET, implying a market capitalization in the low-$20 billion range based on data from trading platforms.
Labcorp at a glance
- Company: Labcorp Holdings Inc.
- ISIN: US50540R4092
- WKN: 895308
- Ticker: LH
- Venue: NYSE
- Price (as of 06/17/2026, 16:35 CET): 264.60 USD
- Market cap: approximately 21,700,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
